ArticleHealth affairs scholar2025
The effect of providing Medicare Advantage enrollees diagnosed with cancer additional time to reassess enrollment.
Article in Health affairs scholar, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Beneficiaries enrolled in Medicare Advantage (MA) and newly diagnosed with cancer may be incentivized to switch coverage, particularly if their MA plan restricts their access to cancer care. Beginning January 2019, the deadline to disenroll from an MA plan changed from February 14 to March 31 and, for the first time, beneficiaries could switch to a different MA plan as opposed to having to enter traditional Medicare. Methods: We used 2016-2019 Surveillance, Epidemiology, and End Results (SEER) Medicare data to conduct a difference-in-differences analysis, estimating the effect of this new policy on rates of MA plan switching 1 month and 2 months after diagnosis. Results: For beneficiaries diagnosed with cancer in March, the policy was associated with a modest increase in both overall rates of switching and in switching to a new MA plan 1 month after diagnosis. Results indicated that the policy had a modest positive effect on changes in Medicare coverage for enrollees diagnosed in January when outcomes were measured 2 months after diagnosis. Conclusion: Relaxing enrollment rules for MA enrollees may not exacerbate adverse selection into traditional Medicare, given this evidence that beneficiaries with high-cost new diagnoses rarely exercised the option to change their MA plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.